Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria.
Recent clinical and experimental observations showed that specific probiotic microorganisms may provide therapeutic benefits in inflammatory bowel disease. However, a rigorous screening for new candidate probiotic strains with optimized therapeutic properties necessitates also determining possible adverse interactions with the host, particularly in individuals who are not healthy. We have evaluated the persistence of strains of lactic acid bacteria (LAB) in the digestive tracts of mice, their immunomodulation capacity, and their safety in healthy animals and in a colitis model. Following daily administration of 10(9) CFU of viable LAB orally, intragastrically, or intrarectally, the animals' feces were examined for bacterial excretion and cytokines were quantified in intestinal samples by quantitative reverse transcription-PCR. The level of bacterial translocation was assessed in healthy mice and in mice suffering from colitis induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS). Irrespective of the route of administration, the potential probiotic strain Lactobacillus plantarum NCIMB8826 was found to persist for up to 10 days in the digestive tracts of mice. This strain did not induce detrimental effects in healthy or in TNBS-treated animals, as was reflected by the absence of weight loss, intestinal inflammation, modification of cytokine levels in the ileum and colon (healthy mice), and bacterial dissemination (healthy and colitic animals). Moreover, the translocation of endogenous microflora to the mesenteric lymph nodes and spleen was greatly reduced in the TNBS-treated mice after administration of LAB. This property, together with the strain's persistence capacity and innocuousness renders L. plantarum NCIMB8826 an attractive candidate as a probiotic to be used in the prevention or treatment of chronic inflammation.
Pavan
Sonia
S
Bactériologie des Ecosystèmes, Institut Pasteur de Lille, France.
Desreumaux
Pierre
P
Mercenier
Annick
A
D000284:Administration, Oral; D000285:Administration, Rectal; D000818:Animals; D018988:Bacterial Translocation; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy; D003106:Colon / Q000378:metabolism / Q000382:microbiology; D016207:Cytokines / Q000097:blood / Q000378:metabolism; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D007082:Ileum / Q000378:metabolism / Q000382:microbiology; D007107:Immune System / Q000187:drug effects; D015212:Inflammatory Bowel Diseases / Q000628:therapy; D007413:Intestinal Mucosa / Q000382:microbiology; D007778:Lactobacillus / Q000145:classification / Q000302:isolation & purification / Q000502:physiology*; D008198:Lymph Nodes / Q000382:microbiology; D051379:Mice; D019936:Probiotics / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D012333:RNA, Messenger / Q000096:biosynthesis; D012449:Safety; D013045:Species Specificity; D013154:Spleen / Q000382:microbiology; D013270:Stomach; D014302:Trinitrobenzenesulfonic Acid / Q000633:toxicity
D016207:Cytokines; D012333:RNA, Messenger; D014302:Trinitrobenzenesulfonic Acid